Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications across the Americas, Europe, the Middle East, Africa, Asia, and other international markets. Its offerings include cellular and molecular technology products such as syringe and peristaltic infusion pumps, electroporation and electrofusion instruments, amino acid analyzers, and spectrophotometers. The company also provides precision scientific measuring instrumentation, preclinical research platforms, telemetry systems, and respiratory and inhalation exposure systems. It markets through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, contract research organizations, and academic laboratories, primarily under brands including Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco. Founded in 1901, Harvard Bioscience is based in Holliston, Massachusetts.

HBIO▲

Harvard Bioscience raises full-year revenue growth outlook to 3% to 5%

Harvard Bioscience raised its full-year 2026 revenue growth guidance to 3% to 5%, up from a prior range of 2% to 4%, while adjusting its adjusted gross margin target to 57% to 59% from 58% to 60% due to product and geographic mix shifts. Second-quarter revenue came in at $22.7 million, an 11% year-over-year increase that exceeded the company's guidance range, driven by double-digit growth in its CMT and preclinical portfolios. Adjusted gross margin for the quarter was 57%, slightly below expectations because of higher-than-expected sales of lower-margin CMT products and sales in China. The company reaffirmed its full-year adjusted EBITDA growth guidance of 6% to 10% and reiterated that its Project Viking restructuring is expected to deliver $3 million in cost savings in 2027 and $4 million annually thereafter. For the third quarter, Harvard Bioscience expects revenue between $21 million and $22.6 million, with adjusted gross margin of 56% to 58% and adjusted EBITDA of $1.5 million to $2.5 million.

HBIO ▲

Seeking Alpha·38dRead more →